OBIO earnings analysis
What we found in OBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided extract is limited to controls, legal proceedings, risk factors, and other information and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A. Accordingly, current-quarter revenue, margins, EPS, cash flow, liquidity, and working-capital trends cannot be assessed from the supplied filing text. Controls were deemed effective as of June 30, 2026, no material legal proceedings were reported, and management stated that risk factors were unchanged from the 2025 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- No material control changes
- The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
- No material legal proceedings
- The company said it was not currently a party to any material legal proceedings and was not aware of any pending or threatened proceeding expected to materially affect the business, operating results, or financial condition.
- Employee stock plan approved
- Stockholders approved the 2026 Employee Stock Purchase Plan at the June 23, 2026 annual meeting.
- CFO trading plan terminated
- The CFO terminated a Rule 10b5-1 arrangement on May 27, 2026 covering sales of up to 84,000 shares; no shares had been sold under the arrangement at termination.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk disclosures unchanged
- The filing directs investors to the risk factors in Part I, Item 1A of the 2025 10-K and states that there have been no material changes. The provided extract does not quantify the underlying risks.
- Controls cannot ensure zero errors
- The company cautions that its control systems provide only reasonable, not absolute, assurance and may not prevent all errors or fraud; management cited resource constraints as an inherent limitation.
- Equity-plan disclosure
- The CFO's terminated Rule 10b5-1 plan had authorized sales of up to 84,000 shares, although no shares were sold before termination.
What they said about what is next.
The provided 10-Q extract contains no quantitative revenue, EPS, liquidity, or operating outlook. It states that risk factors are incorporated from the 2025 10-K and does not provide numeric guidance.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Orchestra BioMed's Q1 2026 results reflect a decrease in total revenue (down 87% YoY), primarily due to the termination of the Terumo Agreement leading to a complete halt of partnership revenue. Gross margin improved to…
- 10-K · March 12, 2026
- Orchestra BioMed positions itself as a partnership‑enabled biomedical company, advancing two flagship candidates (AVIM Therapy with Medtronic and Virtue SAB) through pivotal trials while sharing development and…
- 10-Q · November 12, 2024
- Orchestra BioMed reported Q3 revenue of $987,000 (up from $419,000 in the year-ago quarter), driven by partnership revenue of $803,000 and product revenue of $184,000. Gross margin remained high at ~93.1% while…
- 10-Q · May 13, 2024
- Orchestra BioMed reported total revenue of $620,000 for the three months ended March 31, 2024, down from $1,164,000 in the prior-year quarter, while net loss widened to $13,463,000 (EPS of -$0.38) though EPS slightly…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever